Maxim analyst Jason McCarthy said the phase I data for JCAR014 in relapsed/refractory Chronic Lymphocytic Leukemia presented by Juno at the ASH meeting was "impressive," but noted that one patient died from grade 5 CRS and cerebral edema, which is the same cause of death that has placed the JCAR015 ROCKET study on hold and driven the stock's valuation to its lows. While he has concerns around cerebral edema for JCAR014, McCarthy said that the patients being treated are very sick and he sees the clinical benefit as outweighing the risks. He remains a believer in JCAR014, JCAR017 and Juno's other CAR programs and keeps a Buy rating on the stock.